ABL Diagnostics targets acquisition of two Vela group entities in Asia and the United States
The French molecular diagnostics specialist has signed a non-binding letter of intent for the acquisition of 100% of two companies from the Vela group.
The transaction would extend its commercial presence to Asia-Pacific and the United States, without changing the control or governance of the group.
A letter of intent to acquire two Vela entities
ABL Diagnostics (Euronext Paris: ABLD) announced on September 21, 2026 the signing of a non-binding letter of intent with a view to acquiring the entire share capital of Vela Operations Singapore Pte. Ltd. and Vela Diagnostics USA Inc.
The letter of intent was concluded between Advanced Biological Laboratories S.A. (parent company of ABL), ABL Texcell Diagnostics S.A. and VDH Holding Pte. Ltd., parent company of the Vela group acting as owner and seller of the two entities concerned.
According to the group, this project follows the implementation of an exclusive distribution agreement for Vela Diagnostics solutions in the EMEA zone. This agreement had previously been presented as one of the structuring pillars of the partnership between ABL Texcell Diagnostics and Vela Diagnostics.
The planned acquisition would allow the company to extend its operational and commercial scope to two additional territories: Asia-Pacific and the United States. The group states that this transaction would strengthen its position in the global market for molecular diagnostics of infectious diseases.
The company specifies that the letter of intent sets out the general framework for discussions between the parties. It is non-binding with respect to the completion of the acquisition and creates, at this stage, no obligation to carry the transaction through to completion, except for provisions expressly identified as binding.
A transaction subject to several conditions
The completion of the transaction remains subject to several conditions set out by the company.
The group cites the satisfactory completion of due diligence work, the negotiation and execution of final agreements, the final determination of the transaction scope, the fulfillment of customary prerequisites and the obtaining of any necessary social, regulatory or stock exchange authorizations.
ABL Diagnostics indicates that, if the transaction were to be completed, it would not result in any change of control of ABL Texcell Diagnostics or Advanced Biological Laboratories S.A. The governance and control of both companies would remain unchanged.
The company adds that the parties will continue due diligence work as well as discussions relating to the final documentation of the transaction. It specifies that at this stage, no assurance can be given regarding the outcome of negotiations, the execution of final agreements or the actual completion of the planned acquisition.
Management statements on the project
Dr. Chalom Sayada, Chief Executive Officer of ABL Texcell Diagnostics and co-founder of Advanced Biological Laboratories, presented this project as an extension of the exclusive distribution agreement concluded with Vela Diagnostics for the EMEA zone.
According to him, the planned acquisition of Vela Operations Singapore and Vela Diagnostics USA would provide ABL Texcell Diagnostics with a strengthened international presence directly covering EMEA, Asia-Pacific and the United States.
He indicated that the transaction would make it possible to bring together technological, industrial, regulatory and commercial capabilities within the same international platform, while maintaining, in his terms, a disciplined and rigorous approach in the evaluation and execution of the transaction.
